CME examination Identification No. 89].]02 Instructions for Category I CME credit appear in the front advertising section. See last page of Contents for page number. Questions 1-33, Miller S1. J AM ACAD DERMATOL 1991;24:161-75. Directions for questions 1-16: Give single best response. 1. The sex ratio (male/female) of human basal cell carcinomas is approximately a.0.7:1 b. 1:1 c. 1:1.3 d. 1:1.7 e. 1:2.1 2. Studies of enzymes in a basal cell carcinoma are most likely to be of use to a. determine degree of invasiveness b. determine cell type of origin of the tumor c. detect the nevoid basal cell carcinoma syndrome d. determine whether the tumor was induced by ex- posure to arsenic e. differentiate a metastatic basal cell carcinoma from other cancers of adnexal or glandular origin 3. Which of the following becomes significantly de- pressed after the age of 50 years? a. Graft rejection b. Cytotoxicity against tumor cells c. Reactivity to antigens d. Reactivity to mitogens e. All of the above are correct. 4. After more than 200 treatments with PUVA, the chance of a basal cell carcinoma developing is (approximately) a. less than that in an untreated person b. about the same as that in an untreated person c. twice that in an untreated person d. five times that in an untreated person e. 30 times that in an untreated person 5. After more than 200 treatments with PUVA, the chance of a squamous cell carcinoma developing is (approximately) a. less than that in an untreated person b. about the same as that in an untreated person c. twice that in an untreated person d. five times that in an untreated person e. 30 times that in an untreated person 6. The majority of inflammatory cells that infiltrate basal cell carcinomas are a. T lymphocytes b. B lymphocytes c. natural killer cells d. macrophages e. Langerhans cells 176 7. Which of the following carcinogens is most likely to produce significant numbers of basal cell carcinomas as well as squamous cell carcinomas? a. Methyl methanesulfonate b. Arsenic c. Methylcholanthrene d. Ethyl methanesulfonate e. Methyl nitronitrosoguanine 8. Basal cell carcinomas occur in approximately what proportion of persons with the nevoid basal cell car- cinoma syndrome? a.lO% b.30% c.50% d.80% e. 100% 9. The monoclonal antibody, identifies a. pan-T cells b. helper T cells c. suppressor/cytotoxic T cells d. B cells e. natural killer cells 10. The monoclonal antibodY, Leu-3a, identifies a. pan-T cells b. helper T cells c. suppressor/cytotoxic T cells d. B cells e. natural killer cells 11. The incidence of basal cell carcinomas is greatly re- duced in a. patients with xeroderma pigmentosum 2 years af- ter discontinuation of systemic retinoid treatment b. patients with a history of arsenic exposure 3 years after discontinuation of systemic retinoid therapy c. patients with the nevoid basal cell carcinoma syn- drome 6 months after discontinuation of systemic retinoid therapy d. patients with xeroderma pigmentosum currently receiving systemic retinoid therapy e. none of the above is correct. 12. Treatment with which of the following has been con- sistently successful in several studies in the eradica- tion of multiple basal cell carcinomas? a. Interferon alfa 2 b. Interferon-a c. Interleukin 1 d. Interleukin 2 e. None of the above is correct. CME examination Identification No. 89].]02 Instructions for Category I CME credit appear in the front advertising section. See last page of Contents for page number. Questions 1-33, Miller S1. J AM ACAD DERMATOL 1991;24:161-75. Directions for questions 1-16: Give single best response. 1. The sex ratio (male/female) of human basal cell carcinomas is approximately a.0.7:1 b. 1:1 c. 1:1.3 d. 1:1.7 e. 1:2.1 2. Studies of enzymes in a basal cell carcinoma are most likely to be of use to a. determine degree of invasiveness b. determine cell type of origin of the tumor c. detect the nevoid basal cell carcinoma syndrome d. determine whether the tumor was induced by ex- posure to arsenic e. differentiate a metastatic basal cell carcinoma from other cancers of adnexal or glandular origin 3. Which of the following becomes significantly de- pressed after the age of 50 years? a. Graft rejection b. Cytotoxicity against tumor cells c. Reactivity to antigens d. Reactivity to mitogens e. All of the above are correct. 4. After more than 200 treatments with PUVA, the chance of a basal cell carcinoma developing is (approximately) a. less than that in an untreated person b. about the same as that in an untreated person c. twice that in an untreated person d. five times that in an untreated person e. 30 times that in an untreated person 5. After more than 200 treatments with PUVA, the chance of a squamous cell carcinoma developing is (approximately) a. less than that in an untreated person b. about the same as that in an untreated person c. twice that in an untreated person d. five times that in an untreated person e. 30 times that in an untreated person 6. The majority of inflammatory cells that infiltrate basal cell carcinomas are a. T lymphocytes b. B lymphocytes c. natural killer cells d. macrophages e. Langerhans cells 176 7. Which of the following carcinogens is most likely to produce significant numbers of basal cell carcinomas as well as squamous cell carcinomas? a. Methyl methanesulfonate b. Arsenic c. Methylcholanthrene d. Ethyl methanesulfonate e. Methyl nitronitrosoguanine 8. Basal cell carcinomas occur in approximately what proportion of persons with the nevoid basal cell car- cinoma syndrome? a.lO% b.30% c.50% d.80% e. 100% 9. The monoclonal antibody, identifies a. pan-T cells b. helper T cells c. suppressor/cytotoxic T cells d. B cells e. natural killer cells 10. The monoclonal antibodY, Leu-3a, identifies a. pan-T cells b. helper T cells c. suppressor/cytotoxic T cells d. B cells e. natural killer cells 11. The incidence of basal cell carcinomas is greatly re- duced in a. patients with xeroderma pigmentosum 2 years af- ter discontinuation of systemic retinoid treatment b. patients with a history of arsenic exposure 3 years after discontinuation of systemic retinoid therapy c. patients with the nevoid basal cell carcinoma syn- drome 6 months after discontinuation of systemic retinoid therapy d. patients with xeroderma pigmentosum currently receiving systemic retinoid therapy e. none of the above is correct. 12. Treatment with which of the following has been con- sistently successful in several studies in the eradica- tion of multiple basal cell carcinomas? a. Interferon alfa 2 b. Interferon-a c. Interleukin 1 d. Interleukin 2 e. None of the above is correct.
Transcript
CME examination Identification No. 89].]02
Instructions for Category I CME credit appear in the front advertising section. See last page of Contents for page number.
Questions 1-33, Miller S1. J AM ACAD DERMATOL1991;24:161-75.
Directions for questions 1-16: Give single bestresponse.
1. The sex ratio (male/female) of human basal cellcarcinomas is approximatelya.0.7:1b. 1:1c. 1:1.3d. 1:1.7e. 1:2.1
2. Studies ofenzymes in a basal cell carcinoma are mostlikely to be of use toa. determine degree of invasivenessb. determine cell type of origin of the tumorc. detect the nevoid basal cell carcinoma syndromed. determine whether the tumor was induced by ex
posure to arsenice. differentiate a metastatic basal cell carcinoma
from other cancers of adnexal or glandular origin3. Which of the following becomes significantly de
pressed after the age of 50 years?a. Graft rejectionb. Cytotoxicity against tumor cellsc. Reactivity to antigensd. Reactivity to mitogense. All of the above are correct.
4. After more than 200 treatments with PUVA, thechance of a basal cell carcinoma developing is(approximately)a. less than that in an untreated personb. about the same as that in an untreated personc. twice that in an untreated persond. five times that in an untreated persone. 30 times that in an untreated person
5. After more than 200 treatments with PUVA, thechance of a squamous cell carcinoma developing is(approximately)a. less than that in an untreated personb. about the same as that in an untreated personc. twice that in an untreated persond. five times that in an untreated persone. 30 times that in an untreated person
6. The majority of inflammatory cells that infiltratebasal cell carcinomas area. T lymphocytesb. B lymphocytesc. natural killer cellsd. macrophagese. Langerhans cells
176
7. Which of the following carcinogens is most likely toproduce significant numbers ofbasal cell carcinomasas well as squamous cell carcinomas?a. Methyl methanesulfonateb. Arsenicc. Methylcholanthrened. Ethyl methanesulfonatee. Methyl nitronitrosoguanine
8. Basal cell carcinomas occur in approximately whatproportion of persons with the nevoid basal cell carcinoma syndrome?a.lO%b.30%c.50%d.80%e. 100%
9. The monoclonal antibody, Leu-2a~ identifiesa. pan-T cellsb. helper T cellsc. suppressor/cytotoxic T cellsd. B cellse. natural killer cells
10. The monoclonal antibodY, Leu-3a, identifiesa. pan-T cellsb. helper T cellsc. suppressor/cytotoxic T cellsd. B cellse. natural killer cells
11. The incidence of basal cell carcinomas is greatly reduced ina. patients with xeroderma pigmentosum 2 years af
ter discontinuation of systemic retinoid treatmentb. patients with a history of arsenic exposure 3 years
after discontinuation of systemic retinoid therapyc. patients with the nevoid basal cell carcinoma syn
drome 6 months after discontinuation of systemicretinoid therapy
d. patients with xeroderma pigmentosum currentlyreceiving systemic retinoid therapy
e. none of the above is correct.12. Treatment with which of the following has been con
sistently successful in several studies in the eradication of multiple basal cell carcinomas?a. Interferon alfa 2b. Interferon-ac. Interleukin 1d. Interleukin 2e. None of the above is correct.
CME examination Identification No. 89].]02
Instructions for Category I CME credit appear in the front advertising section. See last page of Contents for page number.
Questions 1-33, Miller S1. J AM ACAD DERMATOL 1991;24:161-75.
Directions for questions 1-16: Give single bestresponse.
1. The sex ratio (male/female) of human basal cellcarcinomas is approximatelya.0.7:1b. 1:1c. 1:1.3d. 1:1.7e. 1:2.1
2. Studies ofenzymes in a basal cell carcinoma are mostlikely to be of use toa. determine degree of invasivenessb. determine cell type of origin of the tumorc. detect the nevoid basal cell carcinoma syndromed. determine whether the tumor was induced by ex
posure to arsenice. differentiate a metastatic basal cell carcinoma
from other cancers of adnexal or glandular origin3. Which of the following becomes significantly de
pressed after the age of 50 years?a. Graft rejectionb. Cytotoxicity against tumor cellsc. Reactivity to antigensd. Reactivity to mitogense. All of the above are correct.
4. After more than 200 treatments with PUVA, thechance of a basal cell carcinoma developing is(approximately)a. less than that in an untreated personb. about the same as that in an untreated personc. twice that in an untreated persond. five times that in an untreated persone. 30 times that in an untreated person
5. After more than 200 treatments with PUVA, thechance of a squamous cell carcinoma developing is(approximately)a. less than that in an untreated personb. about the same as that in an untreated personc. twice that in an untreated persond. five times that in an untreated persone. 30 times that in an untreated person
6. The majority of inflammatory cells that infiltratebasal cell carcinomas area. T lymphocytesb. B lymphocytesc. natural killer cellsd. macrophagese. Langerhans cells
176
7. Which of the following carcinogens is most likely toproduce significant numbers ofbasal cell carcinomasas well as squamous cell carcinomas?a. Methyl methanesulfonateb. Arsenicc. Methylcholanthrened. Ethyl methanesulfonatee. Methyl nitronitrosoguanine
8. Basal cell carcinomas occur in approximately whatproportion of persons with the nevoid basal cell carcinoma syndrome?a.lO%b.30%c.50%d.80%e. 100%
9. The monoclonal antibody, Leu-2a~ identifiesa. pan-T cellsb. helper T cellsc. suppressor/cytotoxic T cellsd. B cellse. natural killer cells
10. The monoclonal antibodY, Leu-3a, identifiesa. pan-T cellsb. helper T cellsc. suppressor/cytotoxic T cellsd. B cellse. natural killer cells
11. The incidence of basal cell carcinomas is greatly reduced ina. patients with xeroderma pigmentosum 2 years af
ter discontinuation of systemic retinoid treatmentb. patients with a history of arsenic exposure 3 years
after discontinuation of systemic retinoid therapyc. patients with the nevoid basal cell carcinoma syn
drome 6 months after discontinuation of systemicretinoid therapy
d. patients with xeroderma pigmentosum currentlyreceiving systemic retinoid therapy
e. none of the above is correct.12. Treatment with which of the following has been con
sistently successful in several studies in the eradication of multiple basal cell carcinomas?a. Interferon alfa 2b. Interferon-ac. Interleukin 1d. Interleukin 2e. None of the above is correct.
Volume 24Number 2, Part 1February 1991
13. Lymphokine-activated killer (LAK) activity occursin the presence ofa. interferon alfa 2b. interferon-ac. interleukin Id. interleukin 2e. none of the above is correct.
14. Photodynamic therapy for basal cell carcinomas usessystemic administration of hematoporphyrin deriva~
tive or dihematoJX)rphyrin, or local application of tetraphenylporphinesulphonate anda. 254 nm radiationb. 365 nm radiationc. 390 to 400 nm radiationd. 630 nm radiatione. 750 nm radiation
15. The most commonly used topical chemotherapeuticregimen in the treatment ofsuperficial basal cell carcinomas isa. 5-fluorouracilb. cisplatin and doxorubicinc. cyclophosphamided. adriamycin and cisplatine. bleomycin
16. The most commonly used chemotherapeutic agent(s)in systemic treatment ofadvanced basal cell carcinomas is (are)a. 5-fluorouracilb. cisplatin and doxorubicinc. cyclophosphamided. adriamycin and cisplatine. bleomycin
Directionsfor questions 17-21: Select the one lettered item most closely related to each numbereditem.
Directionsfor questions 22-26: For each numbereditem choose the appropriate lettered item.
a. Epidermal growth factorb. Transforming growth factor-ac. Bothd. Neither
22. Most studies have shown this factor to be present innormal epidermis.
CME examination 177
23. This factor has been reported to be present in basalcell carcinomas.
24. Binds to a receptor on cell surfaces.25. Binds to a receptor on cell nuclear membranes.26. Receptor for this ligand is coded by the human neu
gene.
Directions for questions 27-33: Indicate correctanswers. All, some, or none of the choices may becorrect.27. Which of the following is (are) thought to playa sig
nificant role in advancing the development of basalcell carcinomas?a. Thyroxineb. Calcitoninc. Somatostatind. Insuline. Glucagon
28. Which of the following is (are) thought to playa significant role in repressing the development of basalcell carcinomas?a. Thyroxineb. Calcitoninc. Somatostatind. Insuline. Glucagon
29. Which of the following is (are) thought to playa significant role in advancing the development of basalcell carcinomas?a. Prostaglandin E2b. Prostaglandin F2
c. Prostaglandin B4d. 12-Rydroxyeicosatetraenoic acid (HETE)e.1S-RETE
30. Which of the following is (are) thought to playa significant role in repressing the development of basalcell carcinomas?a. Prostaglandin E2b. Prostaglandin F2c. Prostaglandin B4d. 12-HETEe.15-HETE
31. Which ofthefollowing is (are) believed to playa significant role in surveillance of basal cell carcinomas?a. B lymphocytesb. T lymphocytesc. Natural killer cellsd. Lymphokine-activated killer activitye. Interferon
32. Squamous cell carcinomas are less likely than basalcell carcinomas to occur ina. the epidermis overlying a dermatofibromab. nevus sebaceusc. Bazex's syndrome
Volume 24Number 2, Part 1February 1991
13. Lymphokine-activated killer (LAK) activity occursin the presence ofa. interferon alfa 2b. interferon-ac. interleukin Id. interleukin 2e. none of the above is correct.
14. Photodynamic therapy for basal cell carcinomas usessystemic administration of hematoporphyrin deriva~
tive or dihematoJX)rphyrin, or local application of tetraphenylporphinesulphonate anda. 254 nm radiationb. 365 nm radiationc. 390 to 400 nm radiationd. 630 nm radiatione. 750 nm radiation
15. The most commonly used topical chemotherapeuticregimen in the treatment ofsuperficial basal cell carcinomas isa. 5-fluorouracilb. cisplatin and doxorubicinc. cyclophosphamided. adriamycin and cisplatine. bleomycin
16. The most commonly used chemotherapeutic agent(s)in systemic treatment ofadvanced basal cell carcinomas is (are)a. 5-fluorouracilb. cisplatin and doxorubicinc. cyclophosphamided. adriamycin and cisplatine. bleomycin
Directionsfor questions 17-21: Select the one lettered item most closely related to each numbereditem.
Directionsfor questions 22-26: For each numbereditem choose the appropriate lettered item.
a. Epidermal growth factorb. Transforming growth factor-ac. Bothd. Neither
22. Most studies have shown this factor to be present innormal epidermis.
CME examination 177
23. This factor has been reported to be present in basalcell carcinomas.
24. Binds to a receptor on cell surfaces.25. Binds to a receptor on cell nuclear membranes.26. Receptor for this ligand is coded by the human neu
gene.
Directions for questions 27-33: Indicate correctanswers. All, some, or none of the choices may becorrect.27. Which of the following is (are) thought to playa sig
nificant role in advancing the development of basalcell carcinomas?a. Thyroxineb. Calcitoninc. Somatostatind. Insuline. Glucagon
28. Which of the following is (are) thought to playa significant role in repressing the development of basalcell carcinomas?a. Thyroxineb. Calcitoninc. Somatostatind. Insuline. Glucagon
29. Which of the following is (are) thought to playa significant role in advancing the development of basalcell carcinomas?a. Prostaglandin E2b. Prostaglandin F2
c. Prostaglandin B4d. 12-Hydroxyeicosatetraenoic acid (HETE)e.15-HETE
30. Which of the following is (are) thought to playa significant role in repressing the development of basalcell carcinomas?a. Prostaglandin E2b. Prostaglandin F2c. Prostaglandin B4d. 12-HETEe.15-HETE
31. Which ofthefollowing is (are) believed to playa significant role in surveillance of basal cell carcinomas?a. B lymphocytesb. T lymphocytesc. Natural killer cellsd. Lyrnphokine-activated killer activitye. Interferon
32. Squamous cell carcinomas are less likely than basalcell carcinomas to occur ina. the epidermis overlying a dermatofibromab. nevus sebaceusc. Bazex's syndrome
CME examination
d. mucosaee. volar skin
33. Proliferative responses of peripheral T lymphocytesafter exposure to which of the following have beenreported to be reduced in patients with basal cell carcinomas?
Answers to CME examination*
a. Phytohemagglutininb. Concanavalin Ac. Candidad. Staphylococcie. Streptococci
Journal of theAmerican Academy of
Dermatology
Identification No. 891-101
January 1991 issue of the JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Questions 1-33, Miller 8J. JAM ACAD DERMATOL 1991;24:1-13.
1. b (p 1, c 1, pa 1)2. b (p 1, c 2, pa 1)3. d (p I, c 2, pa 1)4. e (p 1, c 2, pa 1)5. a (p 2, c 1, pa 2)6. c (p 2, c 1, pa 2)7. d (p 2, c 1, pa 3)8. c (p 2, c 1, pa 3-e 2, pa 1)9. e (p 3, c 1, pa 1)
10. e (p 4, c 1, pa 4)11. d (p 5, c 1, pa 2)12. e (p 5, c 1, pa 4)13. c (p 1, c 2, pa 2-p 2, c 1, pa 1)14. c (p 1, c 2, pa 2-p 2, c 1, pa 1)15. a (p 1, C 2, pa 2-p 2, c 1, pa 1)16. e (p 2, c 1, pa 1)*p: page; c: column; pa: paragraph.
178
17. b (p 2, C 1, pa 1)18.b (p6,cl,pa3)19. a (p 6, c 1, pa 3)20. b (p 6, c 1, pa 3)21.d (p6,cl,pa3)22.a (p7,cl,pa3)23. d (p 7, c 2, pa 3)24. b (p 6, c 2, pa 4)25.c (p2,cl,pa3)26.b (p2,cl,pa3)27. c (p 2, c 1, pa 3)28. a (p 4, c 2, pa 5)29. b (p 4, c 2, pa 5)30. b (p 4, c 2, pa 5)31. b (p 5, c 2, pa 3)32. a (p 2, c 2, pa 5)33. b (p 2, c 2, pa 5-p 3, c 1, pa 1)
